Recurrence of prostate cancer of rare location: magnetic resonance diagnosis and treatment. Clinical case
https://doi.org/10.17650/1726-9776-2024-20-4-90-97
Abstract
Prostate cancer (PCa) is the second most common cancer in the world, with a steady increase in incidence every year. Regardless of the chosen treatment method for patients with localized PCa, the development of local relapse occurs in at least 15 % of cases. The key point in monitoring patients with PCa today is dynamic monitoring of prostate-specific antigen levels. When biochemical recurrence is detected, the subsequent diagnostic algorithm strategy should be aimed at visualizing the tumor site, which can be local, in the lymph nodes, or metastatic. Multiparametric magnetic resonance imaging can serve as a method for diagnosing and monitoring relapses of PCa located locally or in the lymph nodes of the pelvis. When assessing relapses located in the pelvic area, one should remember possible rare sites of their localization, as demonstrated in our clinical case. The optimal treatment for recurrent PCa is still controversial and requires further study.
About the Authors
V. A. Solodkiy
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997
Competing Interests:
None
A. Yu. Pavlov
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997
Competing Interests:
None
V. A. Rebrikova
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Vera A. Rebrikova.
86 Profsoyuznaya St., Moscow 117997
Competing Interests:
None
A. D. Tsibulskii
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997
Competing Interests:
None
A. V. Kriger
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997
Competing Interests:
None
References
1. Clinical guidelines. Prostate cancer. Ministry of Health of Russia, 2021–2022–2023 (20.01.2023). (In Russ.).
2. Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).
3. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660
4. Bergengren O., Pekala K.R., Matsoukas K. et al. 2022 Update on prostate cancer epidemiology and risk factors – a systematic review. Eur Urol 2023;84(2):191–206. DOI: 10.1016/j.eururo.2023.04.021
5. Siegel D.A., O’Neil M.E., Richards T.B. et al. Prostate cancer incidence and survival, by stage and race/ethnicity – United States, 2001–2017. MMWR Morb Mortal Wkly Rep 2020;69(41):1473–80. DOI: 10.15585/mmwr.mm6941a1
6. Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71(4):618–29. DOI: 10.1016/j.eururo.2016.08.003
7. Glybochko P.V., Alyaev Yu.G., Krupinov G.E. et al. Diagnosis and treatment of local recurrence of prostate cancer using hystoscanning and high-intensity focused ultrasound in patients after radical prostatectomy. Urologiia = Urology 2014;(5):72–6. (In Russ.).
8. Artibani W., Porcaro A.B., De Marco V. et al. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int 2018;100(3):251–62. DOI: 10.1159/000481438
9. Novikov R.V. Radioisotope lymphoscintigraphy in prostate cancer: a modern view on the problem. Eksperimental’naya i klinicheskaya urologiya = Experimental and Clinical Urology 2017;(2). Available at: https://cyberleninka.ru/article/n/radioizotopnaya-limfostsintigrafiya-pri-rake-predstatelnoy-zhelezy-sovremennyy-vzglyad-na-problemu (In Russ.).
10. Ploussard G., Fossati N., Wiegel T. et al. Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature. Eur Urol Oncol 2021;4(2):150–69. DOI: 10.1016/j.euo.2021.01.001
11. Mohler J.L., Antonarakis E.S., Armstrong A.J. et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019;17(5):479–505. DOI: 10.6004/jnccn.2019.0023
12. Turkbey B., Rosenkrantz A.B., Haider M.A. et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76(3):340–51. DOI: 10.1016/j.eururo.2019.02.033
13. Corcoran N.M., Hong M.K., Casey R.G. et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 2011;108(8 Pt 2):E202–10. DOI: 10.1111/j.1464-410X.2011.10119.x
14. García-Barreras S., Sanchez-Salas R., Mejia-Monasterio C. et al. Biochemical recurrence-free conditional probability after radical prostatectomy: a dynamic prognosis. Int J Urol 2019;26(7):725–30. DOI: 10.1111/iju.13982
15. Abbas T.O., Al-Naimi A.R., Yakoob R.A. et al. Prostate cancer metastases to the rectum: a case report. World J Surg Oncol 2011;9:56. DOI: 10.1186/1477-7819-9-56
16. Yoo S., Kim J.K., Jeong I.G. Multiparametric magnetic resonance imaging for prostate cancer: a review and update for urologists. Korean J Urol 2015;56(7):487–97. DOI: 10.4111/kju.2015.56.7.487
17. Sandgren K., Westerlinck P., Jonsson J.H. et al. Imaging for the detection of locoregional recurrences in biochemical progression after radical prostatectomy – a systematic review. Eur Urol Focus 2019;5(4):550–60. DOI: 10.1016/j.euf.2017.11.001
18. Oppenheimer D.C., Weinberg E.P., Hollenberg G.M. et al. Multiparametric magnetic resonance imaging of recurrent prostate cancer. J Clin Imaging Sci 2016;6:18. DOI: 10.4103/2156-7514.181494
19. Barrett T., Gill A.B., Kataoka M.Y. et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magn Reson Med 2012;67(3):778–85. DOI: 10.1002/mrm.23062
20. Hotker A.M., Mazaheri Y., Zheng J. et al. Prostate cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. Eur Radiol 2015;25(9):2665–72. DOI: 10.1007/s00330-015-3688-1
21. Jie C., Rongbo L., Ping T. The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis. Eur Radiol 2014;24(8):1929–41. DOI: 10.1007/s00330-014-3201-2
22. Mocikova I., Babela J., Balaz V. Prostate cancer – the role of magnetic resonance imaging. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156(2):103–7. DOI: 10.5507/bp.2012.025
23. Chen Y.J., Chu W.C., Pu Y.S. et al. Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. J Magn Reson Imaging 2012;36(4):912–9. DOI: 10.1002/jmri.23723
24. Park H., Kim S.H., Kim J.Y. Dynamic contrast-enhanced magnetic resonance imaging for risk stratification in patients with prostate cancer. Quant Imaging Med Surg 2022;12(1):742–51. DOI: 10.21037/qims-21-455
25. Cornford P., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71(4):630–42. DOI: 10.1016/j.eururo.2016.08.002
26. Valle L.F., Lehrer E.J., Markovic D. et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol 2021;80(3):280–92. DOI: 10.1016/j.eururo.2020.11.010
27. Solodkiy V.A., Pavlov A.Yu., Tsybulskiy A.D. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radical radiotherapy. Onkourologiya = Cancer Urology 2016;12(4):81–6. (In Russ.). DOI: 10.17650/1726-9776-2016-12-4-81-86
28. Spratt D.E., Dess R.T., Zumsteg Z.S. et al. A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer. Eur Urol 2018;73(2):156–65. DOI: 10.1016/j.eururo.2017.06.027
29. Schmidt-Hegemann N.S., Zamboglou C., Mason M. et al. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiother Oncol 2023;183:109544. DOI: 10.1016/j.radonc.2023.109544
Review
For citations:
Solodkiy V.A., Pavlov A.Yu., Rebrikova V.A., Tsibulskii A.D., Kriger A.V. Recurrence of prostate cancer of rare location: magnetic resonance diagnosis and treatment. Clinical case. Cancer Urology. 2024;20(4):90-97. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-4-90-97
Views:
144
Email this article 